136 related articles for article (PubMed ID: 9626594)
1. Apomorphine does not influence olfactory thresholds in Parkinson's disease.
Roth J; Radil T; Růzicka E; Jech R; Tichý J
Funct Neurol; 1998; 13(2):99-103. PubMed ID: 9626594
[TBL] [Abstract][Full Text] [Related]
2. [The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].
Roth J; Růzicka E; Mecír P
Cas Lek Cesk; 1994 Nov; 133(21):665-7. PubMed ID: 7805088
[TBL] [Abstract][Full Text] [Related]
3. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
4. Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold.
van Hilten JJ; Wagemans EA; Ghafoerkhan SF; van Laar T
Clin Neuropharmacol; 1997 Oct; 20(5):402-8. PubMed ID: 9331516
[TBL] [Abstract][Full Text] [Related]
5. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
6. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
[TBL] [Abstract][Full Text] [Related]
7. Olfactory dysfunction in Parkinson's disease.
Wszolek ZK; Markopoulou K
Clin Neurosci; 1998; 5(2):94-101. PubMed ID: 10785834
[TBL] [Abstract][Full Text] [Related]
8. Dopamine agonists in the treatment of Parkinson's disease.
Bonuccelli U; Pavese N
Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315
[TBL] [Abstract][Full Text] [Related]
9. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
Hellmann MA; Sabach T; Melamed E; Djaldetti R
Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
[TBL] [Abstract][Full Text] [Related]
10. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography.
Dhawan V; Dhoat S; Williams AJ; Dimarco A; Pal S; Forbes A; Tobías A; Martinez-Martin P; Chaudhuri KR
J Neurol Sci; 2006 Oct; 248(1-2):158-62. PubMed ID: 16780888
[TBL] [Abstract][Full Text] [Related]
11. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
[TBL] [Abstract][Full Text] [Related]
12. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
Winge K; Werdelin LM; Nielsen KK; Stimpel H
Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
[TBL] [Abstract][Full Text] [Related]
13. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
Morgante L; Basile G; Epifanio A; Spina E; Antonini A; Stocchi F; Di Rosa E; Martino G; Marconi R; La Spina P; Nicita-Mauro V; Di Rosa AE
Arch Gerontol Geriatr Suppl; 2004; (9):291-6. PubMed ID: 15207426
[TBL] [Abstract][Full Text] [Related]
14. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
[TBL] [Abstract][Full Text] [Related]
15. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
Vaamonde J; Ibáñez R; Gudín M; Hernández A
Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484
[TBL] [Abstract][Full Text] [Related]
16. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
Mongeon D; Blanchet P; Messier J
Neuroscience; 2009 Jan; 158(2):426-40. PubMed ID: 18996173
[TBL] [Abstract][Full Text] [Related]
17. Retronasal olfactory function in Parkinson's disease.
Landis BN; Cao Van H; Guinand N; Horvath J; Haehner A; Savva E; Hugentobler M; Lacroix JS; Burkhard PR
Laryngoscope; 2009 Nov; 119(11):2280-3. PubMed ID: 19753620
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine in dopaminergic therapy.
Subramony JA
Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
[TBL] [Abstract][Full Text] [Related]
19. Defecatory function in Parkinson's disease: response to apomorphine.
Edwards LL; Quigley EM; Harned RK; Hofman R; Pfeiffer RF
Ann Neurol; 1993 May; 33(5):490-3. PubMed ID: 8498826
[TBL] [Abstract][Full Text] [Related]
20. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
[No Abstract] [Full Text] [Related]
[Next] [New Search]
